Vitiligo Skin Transplantation

Safety and Efficacy of Melanocyte-keratinocyte Transplantation in the Treatment of Vitiligo

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00830713

Acronym

MKTP

Enrollment

Registered

2009-01-28

Start date

2009-01-31

Completion date

2011-10-31

Last updated

2012-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Keywords

vitiligo, skin transplantation, non-cultured, melanocyte, surgery

Brief summary

In vitiligo, the melanocytes are lost from the skin in certain areas. One treatment for vitiligo takes the melanocytes from areas of normal skin and places them on areas of that same person's body which have lost their color. This is called the melanocyte-keratinocyte transplantation procedure (MKTP). This procedure has been used successfully in over 3000 cases in India and Saudi Arabia. The purpose of this study is to see if it is effective when performed at the investigators' institution.

Interventions

PROCEDUREMelanocyte-keratinocyte transplantation procedure (MKTP)

skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Be at least 18 years old 2. Have a diagnosis of vitiligo with no news lesions or growth of old lesions in the past 6 months 3. Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form 4. Agree to follow and undergo all study-related procedures

Exclusion criteria

1. Female patients who are breastfeeding, pregnant, or planning to become pregnant 2. Patients with a history of developing vitiligo or keloids at sites of trauma 3. Patients self-reported as having HIV or Hepatitis C 4. Patients self-reported as having uncontrolled Diabetes Mellitus 5. The investigator feels the patient should not participate in the study for any reason

Design outcomes

Primary

Measure	Time frame	Description
effectiveness of MKTP in treating vitiligo	6 months	Assessed by percent repigmentation (excellent= 100%-95%, good= 94%-65%, fair= 64%-25%, poor= 24%-0%).

Secondary

Measure	Time frame	Description
safety of MKTP in treating vitiligo	6 months	Assessed by frequency of adverse events, including, scarring, infection, etc.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026